guselkumab clinical trial intelligence

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent

This clinical trial evaluates the efficacy and safety of Guselkumab in patients with active psoriatic arthritis who have had an inadequate response or intolerance to one prior anti-TNF alpha agent. The study is sponsored by Janssen Research & Development, LLC and aims to establish Guselkumab as a viable treatment option in this patient population.

Matched by target_normalized: Guselkumab